Back to Clinical Feed
Try:
BMJResearch Highlights
Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial
13 May 20265 min read0 viewsScrapeGraph Pilot
GIST (Key Takeaways)
- AbstractObjective. To investigate whether prophylactic tranexamic acid reduces the incidence of postpartum haemorrhage in women with placenta praevia compared with placebo. DesignRandomised, double blind, placebo controlled, phase 3 study.
- Setting24 maternity units across China between July 2023 and March 2025.Participants1732 women with placenta praevia undergoing caesarean delivery. InterventionsParticipants were randomly (1:1) assigned to receive prophylactic oxytocin and either tranexamic acid (1 g in 10 mL) or placebo (10 mL normal saline) diluted in 40 mL normal saline intravenously over 10 minutes, initiated within five minutes of umbilical cord clamping. Main outcome measuresThe primary outcome was postpartum haemorrhage, defined as calculated estimated blood loss ≥1000 mL or as red cell transfusion within two days after delivery.
- Serious adverse events included thromboembolic events, seizures, acute kidney or liver injury, and maternal death. Results. Of 1732 women with placenta praevia who were randomised, 38 were excluded because they withdrew consent or were determined to be ineligible after randomisation.
- Primary outcome data were available for 99.8% (1691/1694) of the remaining women. Placenta accreta spectrum was diagnosed in 303 participants (17.9%).
Clinical Editorial
Summary
BMJ published a clinical update in Research Highlights on 13 May 2026.
The item focuses on Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
PLOS ONERelated by Specialty
Personality traits and the managerial capacity of community-based facilities providing HIV services to key populations in Kenya and Malawi
Research Highlights • 26 Jun 2026
PLOS ONERelated by Specialty
More than a digestive disorder: Perceived stigma in inflammatory bowel disease patients
Research Highlights • 26 Jun 2026
BMJ OpenRelated by Specialty
Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial
Research Highlights • 25 Jun 2026
BMJ OpenRelated by Specialty
Strategies to increase medications for opioid use disorder in hospital settings in the USA: protocol for a scoping review
Research Highlights • 25 Jun 2026
PLOS MedRelated by Specialty
Association of armed conflict and global measles cases: A structural equation modeling analysis of 193 countries from 2000 to 2023
Research Highlights • 25 Jun 2026
Med News TodayRelated by Specialty
Anti-inflammatory diets may lower dementia risk, even in those with early signs
Research Highlights • 26 Jun 2026
Feed Metadata
Source
BMJ
Category
Research Highlights
Published
13 May 2026
Feed Metadata
Source
BMJ
Category
Research Highlights
Published
13 May 2026